Company Profile
Innolife is dedicated to building an innovative drug development platform based on “regulating regenerative signals in therapy.” We are committed to addressing a series of medical challenges in the treatment and prevention of chronic and age-related ischemic injuries, such as heart failure and myocardial infarction, benefiting patients worldwide.
In collaboration with institutions such as Harvard University and the National Cardiovascular Center of the Chinese Academy of Medical Sciences, Innolife has succeeded in the “regulation of regenerative signals in cardiac therapy.” This success has made “molecular bridging” and “myocardial regeneration” possible. Our core product, INL1, a treatment for heart failure, has been selected by the European Society of Cardiology as one of the “Top 10 Breakthrough Studies of 2023.” It has garnered significant international attention in the medical community, with a cover article in the renowned U.S. medical journal “Today’s Medical Highlights” stating that this new drug is poised to become a new hope for reducing ejection fraction in heart failure patients.
Corporate Speaker
Gavin Li
Vice President
Gavin Li is Vice President at Innolife. Prior to joining Innolife he worked for several multinational pharmaceutical companies such as Johnson & Johnson, Pfizer, Novartis, and Yili Group. He has held key leadership positions in multiple functions such as R&D, Medical, market access, government affairs, marketing, and sales. Under his leadership, Innolife achieved groundbreaking collaborations with institutions like Harvard University and the National Cardiovascular Center, earning recognition from the European Society of Cardiology. Gavin is DrPH. Candidate from Johns Hopkins University received an MBA from the Renmin University of China, Bachelor of Clinical Pharmacy from West China Medical University, and Bachelor of Business Administration from Sichuan University.
Company Website